Interleukin-2 after autologous bone marrow transplantation as consolidative immunotherapy against minimal residual disease.
Recipients of autologous BMT demonstrate clinically significant immune deficiency, particularly involving the T lymphocytes. While quantitatively the immune system generally returns to normal during the first 3 months, there is a prolonged delay in the recovery of qualitative immune functions. T cell proliferation is impaired immediately after transplantation and slowly recovers over a period of more than 1 year. In addition, a defect has been documented in IL-2 producing cells and may be of major importance in the pathophysiology of this immunodeficiency. However, post-ABMT, PHA-stimulated T cells are TAC+ and are able to respond to exogenous IL-2 in vitro. Very early after ABMT, NK and LAK activities of PBMC normalize but are significantly increased in vitro by IL-2. On this basis, a clinical assessment of rIL-2 administration on the immunological reconstitution of ABMT patients and as consolidation immunotherapy against minimal disease has been initiated in a phase I/II study.
Bosly
A
A
Université Catholique de Louvain, Laboratoire d'Oncologie et d'Hématologie Expérimentales, Bruxelles, Belgique.
Brice
P
P
Humblet
Y
Y
Doyen
C
C
Faille
A
A
Chatelain
B
B
Franks
C
C
Gisselbrecht
C
C
Symann
M
M
D016026:Bone Marrow Transplantation / Q000276:immunology*; D003131:Combined Modality Therapy; D006801:Humans; D007376:Interleukin-2 / Q000096:biosynthesis / Q000627:therapeutic use*; D009369:Neoplasms / Q000628:therapy*; D010641:Phenotype; D011994:Recombinant Proteins / Q000627:therapeutic use; D013601:T-Lymphocytes / Q000276:immunology; D014182:Transplantation, Autologous
D007376:Interleukin-2; D011994:Recombinant Proteins